Calquence FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 8, 2022.
FDA Approved: Yes (First approved October 31, 2017)
Brand name: Calquence
Generic name: acalabrutinib
Dosage form: Capsules and Tablets
Treatment for: Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia
Calquence (acalabrutinib) is a highly selective, potent, Bruton tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
Development timeline for Calquence
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.